{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:47:07Z","timestamp":1782964027166,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Annual Medical Science Research Project Plan of the Health Commission of Hebei Province","award":["20200178"],"award-info":[{"award-number":["20200178"]}]},{"name":"2023 Annual Hebei Higher Education Institutions Scientific Research Youth Fund Program of Hebei Education Department","award":["QN2023010"],"award-info":[{"award-number":["QN2023010"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16190-0","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:05:32Z","timestamp":1779084332000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of targeted therapies for glioblastoma: a systematic review and network meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Donghui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhe","family":"Ci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"issue":"12 Suppl 2","key":"16190_CR1","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/neuonc\/noab200","volume":"23","author":"QT Ostrom","year":"2021","unstructured":"Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014\u20132018. Neuro Oncol. 2021;23(12 Suppl 2):iii1\u2013105.","journal-title":"Neuro Oncol"},{"issue":"1","key":"16190_CR2","doi-asserted-by":"publisher","first-page":"9595","DOI":"10.1038\/s41598-020-66608-3","volume":"10","author":"I Zur","year":"2020","unstructured":"Zur I, Tzuk-Shina T, Guriel M, Eran A, Kaidar-Person O. Survival impact of the time gap between surgery and chemo-radiotherapy in Glioblastoma patients. Sci Rep. 2020;10(1):9595.","journal-title":"Sci Rep"},{"issue":"23","key":"16190_CR3","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017;318(23):2306\u201316.","journal-title":"JAMA"},{"key":"16190_CR4","doi-asserted-by":"publisher","first-page":"101896","DOI":"10.1016\/j.ctrv.2019.101896","volume":"80","author":"E Le Rhun","year":"2019","unstructured":"Le Rhun E, Preusser M, Roth P, Reardon DA, van den Bent M, Wen P, Reifenberger G, Weller M. Molecular targeted therapy of glioblastoma. Cancer Treat Rev. 2019;80:101896.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"16190_CR5","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1093\/annonc\/mdy120","volume":"29","author":"HG Wirsching","year":"2018","unstructured":"Wirsching HG, Tabatabai G, Roelcke U, Hottinger AF, J\u00f6rger F, Schmid A, Plasswilm L, Schrimpf D, Mancao C, Capper D, et al. Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. Ann Oncol. 2018;29(6):1423\u201330.","journal-title":"Ann Oncol"},{"issue":"3","key":"16190_CR6","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s11060-016-2065-5","volume":"127","author":"C Balana","year":"2016","unstructured":"Balana C, De Las Penas R, Sep\u00falveda JM, Gil-Gil MJ, Luque R, Gallego O, Carrato C, Sanz C, Reynes G, Herrero A, et al. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. J Neurooncol. 2016;127(3):569\u201379.","journal-title":"J Neurooncol"},{"issue":"12","key":"16190_CR7","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1001\/jamaoncol.2024.4361","volume":"10","author":"JN Sarkaria","year":"2024","unstructured":"Sarkaria JN, Ballman KV, Kizilbash SH, Sulman EP, Giannini C, Friday BB, Butowski NA, Mohile NA, Piccioni DE, Battiste JD, et al. Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial. JAMA Oncol. 2024;10(12):1637\u201344.","journal-title":"JAMA Oncol"},{"issue":"5","key":"16190_CR8","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.trecan.2020.02.010","volume":"6","author":"M Butler","year":"2020","unstructured":"Butler M, Pongor L, Su YT, Xi L, Raffeld M, Quezado M, Trepel J, Aldape K, Pommier Y, Wu J. MGMT Status as a Clinical Biomarker in Glioblastoma. Trends Cancer. 2020;6(5):380\u201391.","journal-title":"Trends Cancer"},{"key":"16190_CR9","doi-asserted-by":"crossref","unstructured":"Ashkan K, Baig Mirza A, Soumpasis C, Syrris C, Kalaitzoglou D, Sharma C, James ZJ, Khoja AK, Ahmed R, Vastani A, et al. MGMT promoter methylation: prognostication beyond treatment response. J Pers Med. 2023;13(6):999.","DOI":"10.3390\/jpm13060999"},{"issue":"11","key":"16190_CR10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384.","journal-title":"Ann Intern Med"},{"issue":"10","key":"16190_CR11","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","volume":"18","author":"M Weller","year":"2017","unstructured":"Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017;18(10):1373\u201385.","journal-title":"Lancet Oncol"},{"issue":"9","key":"16190_CR12","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1093\/neuonc\/noae053","volume":"26","author":"P Roth","year":"2024","unstructured":"Roth P, Gorlia T, Reijneveld JC, de Vos F, Idbaih A, Frenel JS, Le Rhun E, Sepulveda JM, Perry J, Masucci GL, et al. Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial. Neuro Oncol. 2024;26(9):1670\u201382.","journal-title":"Neuro Oncol"},{"issue":"1","key":"16190_CR13","first-page":"vdad124","volume":"5","author":"HW Sim","year":"2023","unstructured":"Sim HW, Wachsmuth L, Barnes EH, Yip S, Koh ES, Hall M, Jennens R, Ashley DM, Verhaak RG, Heimberger AB, et al. NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma. Neurooncol Adv. 2023;5(1):vdad124.","journal-title":"Neurooncol Adv"},{"issue":"1","key":"16190_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/neuonc\/noac099","volume":"25","author":"A Omuro","year":"2023","unstructured":"Omuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T, Sumrall A, Baehring J, van den Bent M, B\u00e4hr O, et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. Neuro Oncol. 2023;25(1):123\u201334.","journal-title":"Neuro Oncol"},{"issue":"2","key":"16190_CR15","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/neuonc\/noac173","volume":"25","author":"AB Lassman","year":"2023","unstructured":"Lassman AB, Pugh SL, Wang TJC, Aldape K, Gan HK, Preusser M, Vogelbaum MA, Sulman EP, Won M, Zhang P, et al. Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. Neuro Oncol. 2023;25(2):339\u201350.","journal-title":"Neuro Oncol"},{"issue":"1","key":"16190_CR16","first-page":"vdad116","volume":"5","author":"TT Batchelor","year":"2023","unstructured":"Batchelor TT, Won M, Chakravarti A, Hadjipanayis CG, Shi W, Ashby LS, Stieber VW, Robins HI, Gray HJ, Voloschin A, et al. NRG\/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma. Neurooncol Adv. 2023;5(1):vdad116.","journal-title":"Neurooncol Adv"},{"issue":"11","key":"16190_CR17","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","volume":"24","author":"M Lim","year":"2022","unstructured":"Lim M, Weller M, Idbaih A, Steinbach J, Finocchiaro G, Raval RR, Ansstas G, Baehring J, Taylor JW, Honnorat J, et al. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol. 2022;24(11):1935\u201349.","journal-title":"Neuro Oncol"},{"issue":"10","key":"16190_CR18","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/neuonc\/noab111","volume":"23","author":"HW Sim","year":"2021","unstructured":"Sim HW, McDonald KL, Lwin Z, Barnes EH, Rosenthal M, Foote MC, Koh ES, Back M, Wheeler H, Sulman EP, et al. A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study. Neuro Oncol. 2021;23(10):1736\u201349.","journal-title":"Neuro Oncol"},{"issue":"19","key":"16190_CR19","doi-asserted-by":"publisher","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-15-3153","volume":"22","author":"W Wick","year":"2016","unstructured":"Wick W, Gorlia T, Bady P, Platten M, van den Bent MJ, Taphoorn MJ, Steuve J, Brandes AA, Hamou MF, Wick A, et al. Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). Clin Cancer Res. 2016;22(19):4797\u2013806.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"16190_CR20","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.ejca.2014.12.019","volume":"51","author":"M Westphal","year":"2015","unstructured":"Westphal M, Heese O, Steinbach JP, Schnell O, Schackert G, Mehdorn M, Schulz D, Simon M, Schlegel U, Senft C, et al. A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. Eur J Cancer. 2015;51(4):522\u201332.","journal-title":"Eur J Cancer"},{"issue":"10","key":"16190_CR21","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","volume":"15","author":"R Stupp","year":"2014","unstructured":"Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071\u2009\u2013\u200922072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1100\u20138.","journal-title":"Lancet Oncol"},{"key":"16190_CR22","unstructured":"Gerriets V, Kasi A, Bevacizumab. [Updated 2023 Aug 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: [https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482126\/]."},{"key":"16190_CR23","doi-asserted-by":"publisher","first-page":"1394878","DOI":"10.3389\/fphar.2024.1394878","volume":"15","author":"Z Wang","year":"2024","unstructured":"Wang Z, Li J, Guo J, Wei P. Direct antitumor activity of bevacizumab: an overlooked mechanism? Front Pharmacol. 2024;15:1394878.","journal-title":"Front Pharmacol"},{"issue":"5","key":"16190_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325\u201340.","journal-title":"Nat Rev Clin Oncol"},{"key":"16190_CR25","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Central Nervous System Cancers [https:\/\/www.nccn.org\/login?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cns.pdf]."},{"issue":"8","key":"16190_CR26","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrc2442","volume":"8","author":"G Bergers","year":"2008","unstructured":"Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592\u2013603.","journal-title":"Nat Rev Cancer"},{"issue":"15","key":"16190_CR27","doi-asserted-by":"publisher","first-page":"6503","DOI":"10.1007\/s00253-018-9069-3","volume":"102","author":"X Zhang","year":"2018","unstructured":"Zhang X, Wang S, Nan Y, Fan J, Chen W, Luan J, Wang Y, Liang Y, Li S, Tian W, et al. Inhibition of autophagy potentiated the anti-tumor effects of VEGF and CD47 bispecific therapy in glioblastoma. Appl Microbiol Biotechnol. 2018;102(15):6503\u201313.","journal-title":"Appl Microbiol Biotechnol"},{"issue":"5","key":"16190_CR28","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/neuonc\/not236","volume":"16","author":"K Han","year":"2014","unstructured":"Han K, Ren M, Wick W, Abrey L, Das A, Jin J, Reardon DA. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro Oncol. 2014;16(5):696\u2013706.","journal-title":"Neuro Oncol"},{"key":"16190_CR29","doi-asserted-by":"crossref","unstructured":"Talele S, Mohammad AS, Schulz JA, Bauer B, Hartz AMS, Sarkaria JN, et al. Drug delivery to primary and metastatic brain tumors: challenges and opportunities. In: AAPS Advances in the Pharmaceutical Sciences Series. Vol 33. Springer; 2022:723\u201362.","DOI":"10.1007\/978-3-030-88773-5_24"},{"issue":"11","key":"16190_CR30","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1634\/theoncologist.2009-0121","volume":"14","author":"MH Cohen","year":"2009","unstructured":"Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009;14(11):1131\u20138.","journal-title":"Oncologist"},{"key":"16190_CR31","doi-asserted-by":"publisher","first-page":"963689720933241","DOI":"10.1177\/0963689720933241","volume":"29","author":"Y Tang","year":"2020","unstructured":"Tang Y, Qing C, Wang J, Zeng Z. DNA Methylation-based Diagnostic and Prognostic Biomarkers for Glioblastoma. Cell Transpl. 2020;29:963689720933241.","journal-title":"Cell Transpl"},{"issue":"6","key":"16190_CR32","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMoa2215530","volume":"389","author":"M Provencio","year":"2023","unstructured":"Provencio M, Nadal E, Gonz\u00e1lez-Larriba JL, Mart\u00ednez-Mart\u00ed A, Bernab\u00e9 R, Bosch-Barrera J, Casal-Rubio J, Calvo V, Insa A, Ponce S, et al. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2023;389(6):504\u201313.","journal-title":"N Engl J Med"},{"issue":"7","key":"16190_CR33","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1080\/14712598.2020.1749593","volume":"20","author":"L Chiew Woon","year":"2020","unstructured":"Chiew Woon L, Joycelyn Jie Xin L, Su Pin C. Nivolumab for the treatment of hepatocellular carcinoma. Expert Opin Biol Ther. 2020;20(7):687\u201393.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"16190_CR34","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.21.02229","volume":"40","author":"JD Wolchok","year":"2022","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2022;40(2):127\u201337.","journal-title":"J Clin Oncol"},{"issue":"12","key":"16190_CR35","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s10147-021-02028-1","volume":"26","author":"T Aoki","year":"2021","unstructured":"Aoki T, Kagawa N, Sugiyama K, Wakabayashi T, Arakawa Y, Yamaguchi S, Tanaka S, Ishikawa E, Muragaki Y, Nagane M, et al. Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study. Int J Clin Oncol. 2021;26(12):2205\u201315.","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"16190_CR36","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, B\u00e4hr O, et al. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6(7):1003\u201310.","journal-title":"JAMA Oncol"},{"issue":"3","key":"16190_CR37","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","volume":"25","author":"J Zhao","year":"2019","unstructured":"Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A, et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med. 2019;25(3):462\u20139.","journal-title":"Nat Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16190-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16190-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16190-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:03:50Z","timestamp":1782961430000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16190-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16190"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16190-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This research protocol has been registered with the PROSPERO International Prospective Systematic Reviews Registry (Registration Number: CRD420251010579).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"806"}}